SF3B1 and myelodysplastic syndrome: Above all, we and others have confirmed that around 98% of MDS/AML cases with inv(3)/t(3;3) have mutations in genes involved in RAS/RTK signaling pathways and around 30% of patients possess SF3B1 mutation.14 These data strongly indicate leukemogenic relevance of combinations between inv(3)/t(3;3) and RAS/RTK signaling or SF3B1 mutation, which require future mechanistic investigation.